Two pivotal trials that have contributed substantially to our understanding of their renal benefits are: the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial evaluated canagliflozin, an SGLT2 inhibitor in patients with type 2 diabetes and established DKD. This evidence concerns the gene SLC5A2 and diabetic kidney disease.